We noted you are experiencing viewing problems
- 
        
        Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
 - 
        
        Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. - 
        
        No luck yet? More tips for troubleshooting viewing issues
 - 
        
        Contact HST Support access@hstalks.com
 
- 
        Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
 - 
        For additional help, please don't hesitate to contact HST support access@hstalks.com
 
We hope you have enjoyed this limited-length demo
                    
                    This is a limited length demo talk; you may
                    
                      login or
                    
                    review methods of
                    obtaining more access.
                  
                
                
              Printable Handouts
Navigable Slide Index
- Introduction
 - Tissue engineering
 - Historical perspective
 - The culture of organs
 - Biomedical devices and diagnostics industry: 2002
 - Medical implant industry
 - Tissue engineering and the implant industry
 - Spare body parts
 - Approved tissue products
 - DERMAGRAFT on traumatic wounds
 - Tissue engineered skin substitutes
 - 8th annual hilton head workshop panel discussion
 - Off-the-shelf availability
 - Cell source can be a "show stopper"
 - Use of autogous cells
 - Use of allogeneic cells
 - Embryonic stem cells
 - "Flavors" of pluripotency exist
 - Differentiation of embryonic stem cells
 - Bone marrow-derived cells
 - Scaffold strategies
 - The matrix and cell function
 - Cells in 2D configuration versus 3D configuration
 - Bioreactor technology (1)
 - Bioreactor technology (2)
 - In vivo versus the in vitro bioreactor
 - Development of a cell-seeded scaffold
 - Integration into the living systems
 - Some tissue engineering applications
 - Combination products
 - Therapeutic products
 - What are some of the issues?
 - Testing really begins after FDA approval
 - Key industry trends since 2000
 - Problems encountered by companies
 - Advanced tissue sciences: a case study
 - Status of industry: 2006
 - Medtronic, inc.
 - MG biotherapeutics
 - Tissue engineering 2006
 - Some research challenges
 - Advances envisioned
 - The industry of the future
 
Topics Covered
- Historical perspective
 - Biomedical devices and diagnostics industry
 - Medical implant industry
 - Approved tissue products
 - Dermagraft
 - Tissue engineered skin substitutes
 - Cell source
 - Matrix
 - Immune tolerance
 - Off-the-shelf availability
 - Embryonic stem cells
 - Scaffolds
 - Bioreactor technology
 - Integration into the living system
 - Therapeutic products
 - Key industry trends
 - Advances envisioned
 
Talk Citation
Nerem, R. (2007, October 1). Tissue engineering: the science, the technology and the industry [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2025, from https://doi.org/10.69645/CPCC1093.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Robert Nerem has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.